Valeant to acquire Salix in $14.5 bln deal

NEW YORK, Feb 22 (Reuters) – Valeant Pharmaceuticals International Inc. agreed to acquire Salix Pharmaceuticals Ltd. for $158.00 per share, or a total enterprise value of $14.5 billion, the two…

Leave a Reply

Read the original at Reuters: Mergers News.